Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Drug: Pirtobrutinib for relapsed or refractory mantle cell lymphoma
Study: Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120) Efficacy: ORR: 50% [41-59] DoR: 8.3 mos [5.7 mos-NR] 6 mos DoR: 65.3%
New Protocol – Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Study: Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344) Efficacy: 24 month OS: 24.9% vs. 10.4% ORR:
New Protocol – Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Study: Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344) Efficacy: 24 month OS: 24.9% vs. 10.4% ORR: